Latest News

Newsletter June 2017

CEO’s comments We have received many positive reactions and relevant questions since we announced our plans to acquire Phase II substance Rabeximod from OxyPharma. Naturally, a brief media release cannot provide comprehensive information about all the various aspects related to such an acquisition, so we will be looking to provide Cyxone shareholders with information in […]

Read More

MedUni Vienna technology wins Recognition Prize in the science2business awards

A joint project between MedUni Vienna and Freiburg University Hospital, using cyclotides as a treatment for multiple sclerosis, was awarded the Recognition Prize in the science2business awards. This development is an example of a successful transfer of innovation from research to the business world. Read the article published on Medical University of Vienna’s homepage

Read More

Newsletter April 2017

CEO’s comments I hope that you have all had a happy and pleasant Easter, even if the weather was rather patchy at times. In March and April, Cyxone, together with researchers in Vienna, Freiburg and our strategic partner Sourcia, processed the results of the T20K study with a view to developing a coherent plan to […]

Read More

Newsletter March 2017

This issue of the newsletter is a little later than planned due to two international events, Swiss Nordic Bio and Sachs Forum, which were held in the past two months. Because I presented Cyxone and how T20K can combat MS in presentations at both events, a certain degree of preparation was necessary to deliver as […]

Read More

Newsletter February 2017

A message from the CEO We learnt a great deal about T20K in 2016! Over the past six months, we have analysed a number of T20K’s key characteristics according to the plans we announced prior to floatation in June 2016. We now know that T20K is easier to chemically synthesize, and it appears to be […]

Read More